Infliximab

Common brands: Remicade, Methotrexate, Renflexis, Rasuvo, Trexall

Top reporter: Janssen Biotech, Inc.

Tumor Necrosis Factor Blocker [EPC]Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Aminosalicylate [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
214,259
Total Reports
66,277
Serious Reports
13,350
Death Reports
30
Reported Reactions
Death Report Ratio: High (6.23%)

Patient Demographics

Male
68,324
Female
117,764

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Infliximab.

# Reaction Reports % of Total
1 DRUG INEFFECTIVE 39,248
9.4%
2 OFF LABEL USE 38,111
9.1%
3 CONDITION AGGRAVATED 19,127
4.6%
4 INFUSION RELATED REACTION 18,853
4.5%
5 PAIN 18,333
4.4%
6 RHEUMATOID ARTHRITIS 18,284
4.4%
7 ARTHRALGIA 17,319
4.1%
8 FATIGUE 16,395
3.9%
9 PRODUCT USE ISSUE 13,296
3.2%
10 RASH 13,110
3.1%
11 INTENTIONAL PRODUCT USE ISSUE 12,364
2.9%
12 DRUG INTOLERANCE 12,290
2.9%
13 NAUSEA 12,075
2.9%
14 ALOPECIA 11,711
2.8%
15 JOINT SWELLING 11,444
2.7%
16 HEADACHE 10,997
2.6%
17 SYSTEMIC LUPUS ERYTHEMATOSUS 10,555
2.5%
18 ABDOMINAL DISCOMFORT 10,552
2.5%
19 DIARRHOEA 10,507
2.5%
20 DYSPNOEA 10,419
2.5%
21 HYPERSENSITIVITY 10,125
2.4%
22 CONTRAINDICATED PRODUCT ADMINISTERED 9,955
2.4%
23 MALAISE 9,892
2.4%
24 ARTHROPATHY 9,593
2.3%
25 TREATMENT FAILURE 9,390
2.2%
26 CROHN^S DISEASE 9,328
2.2%
27 PYREXIA 9,238
2.2%
28 DRUG HYPERSENSITIVITY 9,186
2.2%
29 WEIGHT INCREASED 8,994
2.1%
30 SYNOVITIS 8,840
2.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.